Completed enrollment in LEGEND’s pivotal cohort with 125 patients in high-risk, BCG-unresponsive NMIBC with carcinoma in situ Reported preliminary 6-month...
Results
Management to hold webcast today at 5:00 pm Eastern New York, N.Y., Dec. 18, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear...
NANO Nuclear Energy Inc. NANO Nuclear Energy Inc. NANO Nuclear Reports Fiscal Year 2025 Financial Results and Provides Business Update...
FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy...
PAPZIMEOS (zopapogene imadenovec-drba) received full approval by the FDA in August PAPZIMEOS launched with a broad label in the US...
Callan JMB Inc. Expanded the Company’s compliance-driven logistics platform into the food sampling industryEntered agreement to install oral drug delivery...
